Shots:

• WuXi Biologics signs an equity agreement with Pfizer to acquire its state-of-the-art biologics manufacturing facilities along with its labor force in Hangzhou- China. The transaction is expected to close in H1’21
• The agreement will boost WuXi Biologics’ commercial DS & DP capabilities to address surging manufacturing demands
• The state-of-the-art 50-000 m2 facilities include DS capacities equipped with 2x2000L single-use bioreactors expandable to 4x2000L (MFG20) and DP capacities of vial filling (DP9) and pre-filled syringe (DP10). Wuxi will commence the production following the deal closure

 ­ Ref: PRNewswire | Image: WuXi Biologics